Rare disease therapies combine high scientific innovation with unique commercialization and access challenges. Patient populations are small, geographically dispersed, and often specialized, requiring precise clinical targeting and robust engagement with specialized centers and advocacy groups. Regulatory pathways are often accelerated but complex, and pricing and reimbursement negotiations must balance patient access with the high cost of development. The emergence of gene and cell therapies, advanced biologics, and personalized medicine further increases R&D complexity, while real-world evidence and patient outcomes are central to securing coverage and demonstrating value. Companies must prioritize pipeline assets, manage clinical trial risk, and sequence launches globally, while remaining responsive to evolving standards of care and evolving healthcare regulations. Geopolitical considerations, including pricing constraints, MFN clauses, and international market dynamics, also influence market entry and access strategies.

We help rare disease companies navigate these challenges across the full spectrum of capabilities.

  • Corporate Strategy: we define global ambitions, prioritize portfolios, design business models, assess market opportunities, and develop multi-year growth plans, including market entry, partnerships, and alliances tailored to rare disease ecosystems
  • Customer Insights: we map stakeholders, capture the voice of patients, caregivers, prescribers, and payers, and refine value propositions to ensure relevance and differentiation
  • Commercial Strategy: we design go-to-market models, launch readiness plans, commercial excellence programs, competitive benchmarking, and strategic differentiation initiatives that address both clinical and economic complexities
  • Medical Affairs: we support global medical strategy, evidence generation, and medical affairs excellence to strengthen scientific credibility and payer engagement
  • Market Access: we develop global access strategies, reimbursement assessments, public affairs approaches, and value-based healthcare solutions to maximize patient reach
  • R&D and Innovation: we advise on innovation sourcing, portfolio prioritization, lifecycle management, and process optimization to accelerate high-impact programs
  • M&A and Transactions: we support commercial and vendor due diligence, build-up strategies, value creation planning, and post-merger integration
  • Organization and Transformation: we design operating models, governance, and PMO structures adapted to small, specialized teams
  • Manufacturing: we advise on make-or-buy decisions, outsourcing, and cost/margin optimization for complex therapies
  • Digital, Data, and AI: we develop digital roadmaps, advanced analytics, and AI use-case prioritization to improve clinical trial efficiency, patient engagement, and market insights.

By combining deep sector knowledge with end-to-end advisory capabilities, we help rare disease companies accelerate growth, secure access, optimize portfolios, manage risk, and deliver transformative therapies to patients worldwide.